Cargando…

Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan

Background: Multiple sclerosis (MS) is a relapsing, inflammatory, and demyelinating disease of central nervous system showing marked clinical heterogeneity. Many factors might influence the choice of relapse prevention drug, and treatment response varies among patients. Despite the enlargement of di...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashida, Shinji, Ochi, Hirofumi, Hamatani, Mio, Fujii, Chihiro, Nishigori, Ryusei, Kawamura, Kazuyuki, Matsumoto, Sadayuki, Nakagawa, Masanori, Takahashi, Ryosuke, Mizuno, Toshiki, Kondo, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548818/
https://www.ncbi.nlm.nih.gov/pubmed/34721276
http://dx.doi.org/10.3389/fneur.2021.749406
_version_ 1784590662613598208
author Ashida, Shinji
Ochi, Hirofumi
Hamatani, Mio
Fujii, Chihiro
Nishigori, Ryusei
Kawamura, Kazuyuki
Matsumoto, Sadayuki
Nakagawa, Masanori
Takahashi, Ryosuke
Mizuno, Toshiki
Kondo, Takayuki
author_facet Ashida, Shinji
Ochi, Hirofumi
Hamatani, Mio
Fujii, Chihiro
Nishigori, Ryusei
Kawamura, Kazuyuki
Matsumoto, Sadayuki
Nakagawa, Masanori
Takahashi, Ryosuke
Mizuno, Toshiki
Kondo, Takayuki
author_sort Ashida, Shinji
collection PubMed
description Background: Multiple sclerosis (MS) is a relapsing, inflammatory, and demyelinating disease of central nervous system showing marked clinical heterogeneity. Many factors might influence the choice of relapse prevention drug, and treatment response varies among patients. Despite the enlargement of disease-modifying drugs for MS (MS-DMDs), some patients have been treated with corticosteroid and/or immunosuppressant (CS/IS). Objective: To clarify the radiological and laboratory features of MS treated with CS/IS for relapse prevention. Methods: Clinical records including radiological and laboratory findings, and drugs used for relapse prevention were reviewed retrospectively. Results: Out of 92 consecutive MS patients, 25 (27%) were treated with CS/IS. The followings were observed less frequently in patients treated with CS/IS than in those with MS-DMDs: three or more periventricular lesions, ovoid lesions, subcortical lesions, typical contrast-enhancing lesions, negative for serum autoantibodies, and positive for oligoclonal bands in the cerebrospinal fluid. Multiple logistic regression analysis revealed that the absence of typical contrast-enhancing lesions and positivity for serum autoantibodies were independent factors associated with CS/IS prescription (odds ratio 25.027 and 14.537, respectively). Conclusion: In this cohort of Japanese patients clinically diagnosed with MS, radiological and serological findings atypical of MS were observed more frequently in patients treated with CS/IS than in those with MS-DMDs as a part of MS therapy. The absence of contrast-enhancing lesions typical of MS and positivity for serum autoantibodies were independent factors strongly associated with CS/IS use.
format Online
Article
Text
id pubmed-8548818
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85488182021-10-28 Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan Ashida, Shinji Ochi, Hirofumi Hamatani, Mio Fujii, Chihiro Nishigori, Ryusei Kawamura, Kazuyuki Matsumoto, Sadayuki Nakagawa, Masanori Takahashi, Ryosuke Mizuno, Toshiki Kondo, Takayuki Front Neurol Neurology Background: Multiple sclerosis (MS) is a relapsing, inflammatory, and demyelinating disease of central nervous system showing marked clinical heterogeneity. Many factors might influence the choice of relapse prevention drug, and treatment response varies among patients. Despite the enlargement of disease-modifying drugs for MS (MS-DMDs), some patients have been treated with corticosteroid and/or immunosuppressant (CS/IS). Objective: To clarify the radiological and laboratory features of MS treated with CS/IS for relapse prevention. Methods: Clinical records including radiological and laboratory findings, and drugs used for relapse prevention were reviewed retrospectively. Results: Out of 92 consecutive MS patients, 25 (27%) were treated with CS/IS. The followings were observed less frequently in patients treated with CS/IS than in those with MS-DMDs: three or more periventricular lesions, ovoid lesions, subcortical lesions, typical contrast-enhancing lesions, negative for serum autoantibodies, and positive for oligoclonal bands in the cerebrospinal fluid. Multiple logistic regression analysis revealed that the absence of typical contrast-enhancing lesions and positivity for serum autoantibodies were independent factors associated with CS/IS prescription (odds ratio 25.027 and 14.537, respectively). Conclusion: In this cohort of Japanese patients clinically diagnosed with MS, radiological and serological findings atypical of MS were observed more frequently in patients treated with CS/IS than in those with MS-DMDs as a part of MS therapy. The absence of contrast-enhancing lesions typical of MS and positivity for serum autoantibodies were independent factors strongly associated with CS/IS use. Frontiers Media S.A. 2021-10-13 /pmc/articles/PMC8548818/ /pubmed/34721276 http://dx.doi.org/10.3389/fneur.2021.749406 Text en Copyright © 2021 Ashida, Ochi, Hamatani, Fujii, Nishigori, Kawamura, Matsumoto, Nakagawa, Takahashi, Mizuno and Kondo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Ashida, Shinji
Ochi, Hirofumi
Hamatani, Mio
Fujii, Chihiro
Nishigori, Ryusei
Kawamura, Kazuyuki
Matsumoto, Sadayuki
Nakagawa, Masanori
Takahashi, Ryosuke
Mizuno, Toshiki
Kondo, Takayuki
Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan
title Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan
title_full Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan
title_fullStr Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan
title_full_unstemmed Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan
title_short Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan
title_sort radiological and laboratory features of multiple sclerosis patients with immunosuppressive therapy: a multicenter retrospective study in japan
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548818/
https://www.ncbi.nlm.nih.gov/pubmed/34721276
http://dx.doi.org/10.3389/fneur.2021.749406
work_keys_str_mv AT ashidashinji radiologicalandlaboratoryfeaturesofmultiplesclerosispatientswithimmunosuppressivetherapyamulticenterretrospectivestudyinjapan
AT ochihirofumi radiologicalandlaboratoryfeaturesofmultiplesclerosispatientswithimmunosuppressivetherapyamulticenterretrospectivestudyinjapan
AT hamatanimio radiologicalandlaboratoryfeaturesofmultiplesclerosispatientswithimmunosuppressivetherapyamulticenterretrospectivestudyinjapan
AT fujiichihiro radiologicalandlaboratoryfeaturesofmultiplesclerosispatientswithimmunosuppressivetherapyamulticenterretrospectivestudyinjapan
AT nishigoriryusei radiologicalandlaboratoryfeaturesofmultiplesclerosispatientswithimmunosuppressivetherapyamulticenterretrospectivestudyinjapan
AT kawamurakazuyuki radiologicalandlaboratoryfeaturesofmultiplesclerosispatientswithimmunosuppressivetherapyamulticenterretrospectivestudyinjapan
AT matsumotosadayuki radiologicalandlaboratoryfeaturesofmultiplesclerosispatientswithimmunosuppressivetherapyamulticenterretrospectivestudyinjapan
AT nakagawamasanori radiologicalandlaboratoryfeaturesofmultiplesclerosispatientswithimmunosuppressivetherapyamulticenterretrospectivestudyinjapan
AT takahashiryosuke radiologicalandlaboratoryfeaturesofmultiplesclerosispatientswithimmunosuppressivetherapyamulticenterretrospectivestudyinjapan
AT mizunotoshiki radiologicalandlaboratoryfeaturesofmultiplesclerosispatientswithimmunosuppressivetherapyamulticenterretrospectivestudyinjapan
AT kondotakayuki radiologicalandlaboratoryfeaturesofmultiplesclerosispatientswithimmunosuppressivetherapyamulticenterretrospectivestudyinjapan